Nkarta to present preclinical data from engineered nk cell platform at sitc 36th annual meeting

South san francisco, calif., oct. 01, 2021 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today announced four presentations at the upcoming society for immunotherapy of cancer (sitc) 36th annual meeting and pre-conference programs to be held november 10-14, 2021.
NKTX Ratings Summary
NKTX Quant Ranking